Cutaneous T-Cell Lymphoma (CTCL)

Also known as: Cutaneous T-cell lymphoma / Cutaneous lymphoma / Lymphoma, T-Cell, Cutaneous / Mycosis fungoides, unspecified site / Mycoses fungoides / Mycosis fungoides NOS / Mycosis fungoides

DrugDrug NameDrug Description
DB00242CladribineAn antineoplastic agent used in the treatment of lymphoproliferative diseases including hairy-cell leukemia.
DB00004Denileukin diftitoxA recombinant DNA-derived cytotoxic protein composed of the amino acid sequences for diphtheria toxin fragments A and B (Met 1-Thr 387)-His followed by the sequences for interleukin-2 (IL-2; Ala 1-Thr 133). It is produced in an E. coli expression system.
DB06813PralatrexatePralatrexate is an antimetabolite for the treatment of relapsed or refractory peripheral T-cell lymphoma. It is more efficiently retained in cancer cells than methotrexate. FDA approved on September 24, 2009.